Canton Strategic (CNTN) vs Invivyd (IVVD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Canton Strategic (CNTN) has outperformed Invivyd (IVVD) over the past year, losing 34.6% versus a loss of 57.3%. Invivyd is the larger company by market cap ($206.4 million vs $165.7 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CNTN | IVVD |
|---|---|---|
| Share price | $2.08 | $0.7004 |
| Market cap | $165.74M | $206.45M |
| 1-day change | -7.96% | -3.87% |
| YTD return | -31.35% | -71.64% |
| 1-year return | -34.59% | -57.29% |
| 5-year return | — | -97.84% |
| EPS (TTM) | $-0.10 | $-0.33 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.89 | $3.07 |
| 52-week low | $1.75 | $0.528 |
| Distance from 52-week high | -69.81% | -77.19% |
| Analyst consensus | — | strong_buy |
| Avg. price target upside | — | +1327.76% |
| Average volume | 758.86K | 4.78M |
| Shares outstanding | 79.68M | 294.76M |
| Employees | 12 | 122 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CNTN has outperformed IVVD by 22.7 percentage points over the past year.
About Canton Strategic
CNTN stock →Canton Strategic Holdings, Inc. engages in the institutional blockchain adoption and digitization of financial markets in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees
About Invivyd
IVVD stock →Invivyd, Inc., together with its subsidiaries, engages in the research, development, commercialization, and sale of antibody therapies for the prevention and treatment of viral infectious diseases in the United States. The company offers Pemivibart, a half-life extended investigational monoclonal antibody for the pre-exposure prophylaxis prevention of COVID-19 in adults and adolescents through injection under the PEMGARDA brand.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 122 employees
CNTN vs IVVD FAQ
Which is bigger, Canton Strategic or Invivyd?
Invivyd (IVVD) is larger, with a market capitalization of $206.45M compared with $165.74M for Canton Strategic (CNTN).
Which stock has performed better over the past year, CNTN or IVVD?
CNTN returned -34.59% over the past 12 months, compared with -57.29% for IVVD (price return, excluding dividends). Past performance does not predict future results.
Are Canton Strategic and Invivyd in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Canton Strategic and Biotechnology: Biological Products (No Diagnostic Substances) for Invivyd.